Effect of Depot Medroxyprogesterone Acetate (DMPA) on Bone Mineral Density in Women of Reproductive Age
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Liu, Y.
Journal of Reproduction and Contraception 20(1): 51-56
2009
ISSN/ISBN: 1001-7844 Document Number: 205847
Document emailed within 1 workday
Related Documents
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Zhou, L.; Liu, Y. 2011: The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83(3): 218-222Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Zhou, L.; Liu, Y. 2011: The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83(3): 218-222
Pongsatha, S.; Ekmahachai, M.; Chaovisitsaree, S.; Suntornlimsiri, N.; Morakote, N. 2009: Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study Journal of the Medical Association of Thailand 92(10): 1263-1267
Wanichsetakul, P.; Kamudhamas, A.; Watanaruangkovit, P.; Siripakarn, Y.; Visutakul, P. 2002: Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception Contraception 65(6): 407-410
Modesto, W.; Bahamondes, M.V.; Silva dos Santos, P.; Fernandes, A.; Dal'Ava, N.; Bahamondes, L. 2014: Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 19(4): 244-249
Rahman, M.; Berenson, A.B. 2010: Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate Obstetrics and Gynecology 115(1): 35-40
Harel, Z.; Johnson, C.Cole.; Gold, M.A.; Cromer, B.; Peterson, E.; Burkman, R.; Stager, M.; Brown, R.; Bruner, A.; Coupey, S.; Hertweck, P.; Bone, H.; Wolter, K.; Nelson, A.; Marshall, S.; Bachrach, L.K. 2010: Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections Contraception 81(4): 281-291
Harel, Z.; Wolter, K.; Gold, M.A.; Cromer, B.; Bruner, A.; Stager, M.; Bachrach, L.; Hertweck, P.; Nelson, A.; Nelson, D.; Coupey, S.; Johnson, C.C.; Burkman, R.; Bone, H. 2010: Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study Journal of Pediatric and Adolescent Gynecology 23(4): 209-214
Tharnprisarn, W.; Taneepanichskul, S. 2002: Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: A cross-sectional study in young Thai women Contraception 66(2): 101-103
Babatunde, O.O.; Forsyth, J.J. 2014: Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health Journal of Bone and Mineral Metabolism 32(3): 305-311
Segall-Gutierrez, P.; Du, J.; Niu, C.; Ge, M.; Tilley, I.; Mizraji, K.; Stanczyk, F.Z. 2012: Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women Contraception 86(6): 739-745
Harel, Z.; Wolter, K.; Gold, M.A.; Cromer, B.; Stager, M.; Johnson, C.C.; Brown, R.; Bruner, A.; Coupey, S.; Hertweck, P.; Bone, H.; Burkman, R.; Nelson, A.; Marshall, S.; Bachrach, L.K. 2010: Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5% Contraception 82(6): 503-512
Beksinska, M.E.; Kleinschmidt, I.; Smit, J.A.; Farley, T.M.M. 2009: Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate Contraception 79(5): 345-349
Lumbiganon, P. 1994: Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary Contraception 49(3): 203-209
Lumbiganon, P. 1994: Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary Contraception 49(3): 203-209
Hu, E.; Ikeako, L.C.; Obiora-Okafor, N.C. 2012: The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 21(3): 266-271
Chaudhri, R.; Rizvi, F.; Afzal, M. 2010: Patient satisfaction of depot medroxyprogesterone acetate (dmpa-sc) injection as contraceptive Jpma. Journal of the Pakistan Medical Association 60(7): 536-540
Hu, E.; Ikeako, L.C.; Obiora-Okafor, N.C. 2012: The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 21(3): 266-271
Cromer, B. 2005: In favor of continued use of depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents Journal of Pediatric and Adolescent Gynecology 18(3): 183-187
Omar, H.; Kives, S. 2005: Depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents: what is next after the FDA black box warning Journal of Pediatric and Adolescent Gynecology 18(3): 183